Logo image of DBV.PA

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

EPA:DBV - FR0010417345 - Common Stock

1.578 EUR
+0.07 (+4.37%)
Last: 9/10/2025, 7:00:00 PM
Fundamental Rating

2

DBV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 70 industry peers in the Biotechnology industry. DBV has a bad profitability rating. Also its financial health evaluation is rather negative. DBV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DBV had negative earnings in the past year.
DBV had a negative operating cash flow in the past year.
In the past 5 years DBV always reported negative net income.
DBV had a negative operating cash flow in each of the past 5 years.
DBV.PA Yearly Net Income VS EBIT VS OCF VS FCFDBV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

DBV's Return On Assets of -85.56% is on the low side compared to the rest of the industry. DBV is outperformed by 71.43% of its industry peers.
DBV has a Return On Equity of -142.22%. This is comparable to the rest of the industry: DBV outperforms 44.29% of its industry peers.
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBV.PA Yearly ROA, ROE, ROICDBV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

With an excellent Gross Margin value of 91.34%, DBV belongs to the best of the industry, outperforming 87.14% of the companies in the same industry.
DBV's Gross Margin has declined in the last couple of years.
DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBV.PA Yearly Profit, Operating, Gross MarginsDBV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

3

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBV has more shares outstanding than it did 1 year ago.
DBV has more shares outstanding than it did 5 years ago.
DBV has a worse debt/assets ratio than last year.
DBV.PA Yearly Shares OutstandingDBV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DBV.PA Yearly Total Debt VS Total AssetsDBV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

DBV has an Altman-Z score of -3.02. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DBV (-3.02) is worse than 61.43% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that DBV is not too dependend on debt financing.
DBV has a Debt to Equity ratio of 0.08. This is in the better half of the industry: DBV outperforms 67.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -3.02
ROIC/WACCN/A
WACC7.36%
DBV.PA Yearly LT Debt VS Equity VS FCFDBV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.
DBV has a Current ratio (2.45) which is in line with its industry peers.
DBV has a Quick Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
DBV's Quick ratio of 2.45 is fine compared to the rest of the industry. DBV outperforms 62.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
DBV.PA Yearly Current Assets VS Current LiabilitesDBV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DBV have decreased strongly by -22.83% in the last year.
DBV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -72.49%.
Measured over the past years, DBV shows a very negative growth in Revenue. The Revenue has been decreasing by -22.35% on average per year.
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%

3.2 Future

DBV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.50% yearly.
DBV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 146.91% yearly.
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue Next Year2930.57%
Revenue Next 2Y1763.33%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBV.PA Yearly Revenue VS EstimatesDBV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
DBV.PA Yearly EPS VS EstimatesDBV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBV.PA Price Earnings VS Forward Price EarningsDBV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBV.PA Per share dataDBV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

DBV's earnings are expected to grow with 23.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.64%
EPS Next 3Y23.5%

More info and screens

0

5. Dividend

5.1 Amount

DBV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA

EPA:DBV (9/10/2025, 7:00:00 PM)

1.578

+0.07 (+4.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)N/A N/A
Inst Owners48.3%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap43.18M
Analysts80
Price Target3.96 (150.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.65%
EPS NY rev (3m)6.65%
Revenue NQ rev (1m)-29.19%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.34
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0.12
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.34%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.61%
Cap/Sales 8.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -3.02
F-Score2
WACC7.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%
Revenue Next Year2930.57%
Revenue Next 2Y1763.33%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%
EBIT growth 1Y-31.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A